Thus, by blocking TC-HR and Alt-NHEJ simultaneously, the combination of TRDMT1i with PARPi or POLθi induces a “synthetic lethality” in HR-proficient cancer cells (Fig. 6h). The gene discussed is ENSG00000223804; the disease is cancer.